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Previous work from our laboratory has demonstrated that the
Ca#+–calmodulin complex inhibits the intrinsic tyrosine kinase
activity of the epidermal growth factor receptor (EGFR), and
that the receptor can be isolated by Ca#+-dependent calmodulin-
affinity chromatography [San Jose! , Bengurı!a, Geller and
Villalobo (1992) J. Biol. Chem. 267, 15237–15245]. Moreover, we
have demonstrated that the cytosolic juxtamembrane region of
the human receptor (residues 645–660) binds calmodulin in
a Ca#+-dependent manner when this segment forms part of a
recombinant fusion protein [Martı!n-Nieto and Villalobo (1998)
Biochemistry 37, 227–236]. However, demonstration of the direct
interaction between calmodulin and the whole receptor has
remained elusive. In this work, we show that calmodulin, in the
presence of Ca#+, forms part of a high-molecular-mass complex
built upon covalent cross-linkage of the human EGFR immuno-
precipitated from two cell lines overexpressing this receptor.
INTRODUCTION
The epidermal growth factor (EGF) receptor (EGFR) belongs
to the superfamily of tyrosine kinase receptors located in the
plasma membrane that upon ligand binding dimerizes and trans-
phosphorylates. The resulting phosphotyrosine residues in the
receptor recruit adaptor proteins and transduction systems which
initiate signalling events to the cell interior to attain proliferative,
differentiation, cell-survival and even cell-motility responses (for
review, see [1–4]).
Signalling by the EGFR is accompanied in many cell types by
a transient increase in the cytosolic concentration of free Ca#+
(for review, see [5]). This early calcium signal mediates the retro-
inhibition of the intrinsic tyrosine kinase activity of the EGFR
using regulatory Ca#+-dependent serine}threonine-protein kin-
ases that phosphorylate the receptor, such as protein kinase C
[6–10] and calmodulin (CaM)-dependent protein kinase II
[11–13]. In addition, the Ca#+–CaM complex also regulates the
tyrosine kinase activity of the EGFR acting on the receptor itself
[5,14–16].
Thus in previous work from our laboratory we have
demonstrated that the EGFR from rat liver and from murine
fibroblasts overexpressing the human receptor can be isolated by
Ca#+-dependent CaM-affinity chromatography [14–16]. Further-
more, we have also shown that the Ca#+–CaM complex directly
inhibits the intrinsic tyrosine kinase activity of the receptor
[5,14,15]. Moreover, using a recombinant fusion protein, we
proved that the cytosolic juxtamembrane region (residues
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Although several calmodulin-binding proteins co-immuno-
precipitated with the EGFR, suggesting that they interact with
the receptor, we demonstrated using overlay techniques that
biotinylated calmodulin binds directly to the receptor in a Ca#+-
dependent manner without the mediation of any adaptor
calmodulin-binding protein. Calmodulin binds to the EGFR
with an apparent dissociation constant (K «
d
) of approx.
0.2–0.3 lM. Treatment of cells with epidermal growth factor, or
with inhibitors of protein kinase C and calmodulin-dependent
protein kinase II, or treatment of the immunoprecipitated
receptor with alkaline phosphatase, does not significantly affect
the binding of biotinylated calmodulin to the receptor.
Key words: biotinylated calmodulin, calcium, covalent cross-
linkage, overlay.
645–660) of the human EGFR binds CaM in a Ca#+-dependent
fashion, and that there is cross-talk between the binding of CaM
to this receptor segment and the phosphorylation of Thr’&%
by protein kinase C [16]. Hence, the binding of CaM to the
fusion protein prevents Thr’&% phosphorylation, and, con-
versely, the phosphorylation of this residue by protein kinase C
prevents the CaM-binding process [5,16]. The CaM-binding site
under consideration appears to be highly conserved in EGFRs
from different species, as it is identical in human, mouse and
chicken, which underscores its physiological significance [16].
Moreover, although there are some differences in their amino acid
sequences, this site may retain its CaM-binding capacity in other
ErbB receptor family members.
Despite the accumulated evidence, the direct interaction of
CaM with the intact receptor has remained elusive and has not
been demonstrated to date. In this study, we fill this gap by
reporting the direct binding of CaM to the human EGFR
isolated from two cell lines overexpressing this receptor. More-
over, we have demonstrated that the EGFR interacts with other
CaM-binding proteins.
EXPERIMENTAL
Reagents
Monoclonal anti-CaM antibody (a-CaM) developed in mouse
was obtained from Upstate Biotechnology, and monoclonal
anti-EGFR antibodies (a-EGFRs) from clone 528 (recognizing
# 2002 Biochemical Society
500 H. Li and A. Villalobo
the extracellular domain of the human receptor) and from clone
13 (recognizing the intracellular segment 996–1022 of the human
receptor) developed in mouse were obtained from Oncogene and
Transduction Laboratories, respectively. The monoclonal anti-
phosphotyrosine antibody RC20 (a-P-Tyr) conjugated to horse-
radish peroxidase was also obtained from Transduction Labora-
tories. Anti-mouse IgG (Fc-specific) developed in goat and
conjugated to horseradish peroxidase, alkaline phosphatase from
bovine intestinal mucosa, deoxycholic acid (sodium salt), sodium
orthovanadate, leupeptin, pepstatin A, aprotinin, PMA and
PMSF were purchased from Sigma. The prestained molecular-
mass standards for electrophoresis were obtained from Bio-Rad.
From Pierce were purchased bis(sulphosuccinimidyl) suberate
(BS$), EZ-link4 NHS-LC-biotin [succinimidyl-6-(biotinamido)
hexanoate] and streptavidin conjugated to horseradish peroxi-
dase. BioTrace4 PVDF membranes were purchased from Pall
Gelman Laboratory, and ECL4 was obtained from Amersham
Bioscience. Mouse IgG serum fraction, GF109203X †2-[1-(3-
dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-male-
imide· and KN93 were obtained from Calbiochem. Escherichia
coli cultures expressing recombinant rat CaM lacking its N-
terminal methionine and post-translational modifications [17]
was a kind gift of Professor Nobuhiro Hayashi (Fujita Health
University, Aichi, Japan). Other chemicals were of analytical
grade.
Cell cultures
Human epidermoid carcinoma A431 cells and EGFR-T17murine
fibroblasts overexpressing the human EGFR were grown in
Dulbecco’s modified Eagle’s medium supplemented with 10%
(v}v) foetal bovine serum, 2 mM l-glutamine and 40 lg}ml
gentamicin in a humidified atmosphere of 5% (v}v) CO
#
in air
at 37 °C. The cells were maintained overnight in a foetal bovine
serum-free medium before performing the experiments.
Purification of recombinant CaM and preparation of biotinylated
CaM
Recombinant rat CaM was purified from E. coli as described in
[17], except that the soluble cell extract was heated at 95 °C for
5 min before the heat-resistant proteins of the supernatant were
subjected to phenyl-Sepharose chromatography. The concen-
tration of CaM was determined spectrophotometrically at
276 nm using a 1% (w}v) absorption coefficient of 1.8. Purified
CaM was biotinylated using EZ-link4 NHS-LC-biotin as de-
scribed in [18].
EGFR immunoprecipitation
Serum-starved confluent cells grown in dishes of 15 cm diameter
were incubated in the absence and presence of 10 nM EGF for
1–5 min at room temperature. Thereafter, the medium was
removed and 1 ml of a lysis buffer, containing 50 mM Tris}HCl
(pH 8), 150 mM NaCl, 1 mM EGTA, 1% (w}v) Triton X-100,
0.5% (w}v) deoxycholic acid, 1 mM sodium orthovanadate,
1 mM PMSF, 10 lg}ml leupeptin, 10 lg}ml pepstatin A and
10 lg}ml aprotinin, was added and incubated for 30 min on ice.
If not indicated otherwise, the cell lysate was prepared in the
presence of EGTA. The cell extract was collected by centri-
fugation on a bench-top centrifuge at 15600 g
max
for 35 min, and
2–8 mg of solubilized proteins was incubated for 3–12 h in
200 ll of a medium containing 50 mM Tris}HCl (pH 8), 150 mM
NaCl, 1 mM sodium orthovanadate, 1 mM PMSF and 1.5 lg of
a-EGFR (recognizing the extracellular domain) precoupled to
30 ll of a slurry of Protein A–agarose. The beads were collected
by low-speed centrifugation and washed six times in 50 mM
Tris}HCl (pH 8), 150 mM NaCl, 1 mM sodium orthovanadate
and 1 mM PMSF (TNOP buffer). The samples were boiled for
5 min in Laemmli sample buffer, the beads were removed by low-
speed centrifugation, and the supernatant was processed by
SDS}PAGE as described below. Control mock immunoprecipi-
tations were performed using a non-relevant mouse IgG fraction
instead of the a-EGFR, with negative results.
Western-blot analysis
Proteins in the gel were electrotransferred to a PVDF membrane
in a medium containing 48 mM Tris-base, 36.6 mM glycine,
20% (v}v) methanol and 0.04% (w}v) SDS (TGMS medium),
and the proteins were fixed with 0.2% (v}v) glutaraldehyde for
45 min in a medium containing 0.1% (w}v) Tween 20, 100 mM
Tris}HCl (pH 8.8), 500 mM NaCl and 0.25 mM KCl (T-TBS
medium). The PVDF membrane was blocked with 5% (w}v)
BSA in T-TBS medium, and probed with a-P-Tyr conjugated to
horseradish peroxidase, a-EGFR (recognizing the intracellular
domain) or a-CaM at dilutions of 1}1000 to 1}3000. Appropriate
secondary antibodies coupled to horseradish peroxidase at a
dilution of 1}3000 were used as required. The positive bands
were developed using the enhanced chemiluminescence Luminol
(ECL4) method following instructions from the manufacturer.
When required, re-probing the PVDF membrane with a different
antibody was performed after stripping the membrane in a
medium containing 100 mM b-mercapthoethanol, 2% (w}v)
SDS and 62.5 mM Tris}HCl (pH 6.7) at 50 °C for 30 min or
after overnight incubation at room temperature.
CaM cross-linking experiments
Protein A–agarose}a-EGFR beads containing immunoprecipi-
tated EGFR were washed four times in TNOP buffer and
resuspended in a medium containing 20 mM Hepes}NaOH
(pH 7.5), 150 mM NaCl, 0.2 mM CaCl
#
, 1 mM sodium ortho-
vanadate and 1 mM PMSF (linkage buffer). Free CaM or
biotinylated CaM (0.45 lg) was added to 1 ml of the immuno-
precipitated receptor preparation and incubated for 3 h at 4 °C.
Thereafter, 1 mM BS$ was added and incubated for 1 h at
4 °C. Controls containing 1 mM EGTA instead of CaCl
#
were
performed. The beads were washed four times in linkage buffer,
boiled for 5 min in Laemmli sample buffer and processed for
electrophoresis. The proteins were electrotransferred to a PVDF
membrane using TGMS medium, and fixed with 0.2% (v}v)
glutaraldehyde for 45 min in T-TBS medium. The PVDF mem-
brane was blocked with 5% (w}v) BSA in T-TBS medium and
probed with the different antibodies as described above.
When biotinylated CaM was used, streptavidin conjugated to
horseradish peroxidase at a 1}3000 dilution was added and
incubated for 30 min at 37 °C or for 1 h at room temperature.
The positive bands were developed using the ECL4 method
following instructions from the manufacturer. Controls in the
absence of CaM or biotinylated CaM, and in the absence of any
primary antibody, were developed with horseradish peroxidase-
conjugated streptavidin.
CaM overlay experiments
The whole-cell extract or the immunoprecipitated EGFR pre-
pared as described above was subjected to electrophoresis, and
the proteins were electrotransferred to a PVDF membrane using
TGMS medium and fixed with 0.2% (v}v) glutaraldehyde for
45 min in T-TBS medium. The PVDF membrane was blocked
with 5% (w}v) BSA in T-TBS medium and incubated with
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0.45 lg}ml biotinylated CaM in the presence of 0.2 mM CaCl
#
for 30 min at 37 °C or overnight at 4 °C. Controls containing
1 mM EGTA instead of CaCl
#
were performed. After extensive
washing of the PVDF membrane in the same medium, strept-
avidin conjugated to horseradish peroxidase (1}3000 dilution)
was added and incubated for 30 min at 37 °C or for 1 h at room
temperature. The positive bands were developed using the ECL4
method.
Other analytical procedures
Slab gel electrophoreses were performed according to Laemmli
[19] at 12 mA overnight in a linear gradient 5–20% (w}v)
polyacrylamide gel in the presence of 0.1% (w}v) SDS at pH 8.3.
Protein concentrations were determined using bicinchoninic acid
and copper sulphate (BCA method; Sigma) following the manu-
facturer’s instructions and using BSA as a standard. The intensity
of the bands present on the X-ray films after ECL4 development
was quantified by a computer-assisted scanner using the NIH
Image 1.59 program.
RESULTS
Detection of CaM-binding proteins in whole-cell extracts by
overlay with biotinylated CaM
To detect the major CaM-binding proteins present in cell-free
extracts from two cell lines overexpressing the human EGFR, we
Figure 1 CaM-binding proteins in A431 tumour cells and EGFR-T17
fibroblasts
Whole-cell extracts (50 lg of protein) of A431 tumour cells (lanes 1) and EGFR-T17 fibroblasts
(lanes 2) were subjected to overlay with biotinylated CaM in the presence (Ca2+) and absence
(EGTA) of calcium as described in the Experimental section. Non-specific binding was detected
in the absence of biotinylated CaM (Control).
Figure 2 Covalent cross-linkage of CaM to a human EGFR complex
The immunoprecipitated EGFR from 3.5 mg of protein cell extract of A431 tumour cells (A) and
from 2 mg of protein cell extract of EGFR-T17 fibroblasts (B) in non-stimulated cells (fi) or
cells treated with 10 nM EGF for 5 min (›), was subjected to covalent cross-linkage with BS3
in the absence (fi) and presence (›) of CaM as indicated. Separate samples were probed
with an a-EGFR, an a-P-Tyr or an a-CaM as described in the Experimental section.
Experiments performed in the absence of any primary antibody (Control) are also presented. The
arrow points to the approx. 390 kDa complex.
performed overlay experiments using biotinylated CaM. Figure
1 shows that A431 tumour cells (Figure 1, lanes 1) and EGFR-
T17 fibroblasts (Figure 1, lanes 2) contain different proteins that
bind CaM in a Ca#+-dependent manner (Figure 1, Ca#+). Par-
ticularly interesting is a set of high-molecular-mass CaM-binding
proteins in the range of approx. 140–220 kDa, as the EGFR has
an apparent molecular mass of 170 kDa. All the CaM-binding
proteins detected in these experiments require Ca#+ for the
binding process. Indeed, the bands observed in the absence of
calcium (Figure 1, EGTA) bound unspecifically to peroxidase-
conjugated streptavidin, as they were also detected when bio-
tinylated CaM was not used (Figure 1, Control).
Covalent cross-linkage of CaM to a human EGFR complex
To determine whether CaM could be associated with the EGFR,
we performed cross-linkage experiments using the immuno-
precipitated receptor from A431 tumour cells (Figure 2A) and
EGFR-T17 fibroblasts (Figure 2B). Treatment of the immuno-
precipitated receptor with the cross-linking agent BS$ induced
the formation of a high-molecular-mass complex of approx.
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Figure 3 Covalent cross-linkage of biotinylated CaM to a human EGFR
complex
The immunoprecipitated EGFR from 3 mg of protein cell extract of A431 tumour cells (A) and
from 2.5 mg of protein cell extract of EGFR-T17 fibroblasts (B) in cells treated (›) or not (fi)
with 10 nM EGF for 5 min, were subjected to covalent cross-linkage with BS3 in the presence
of 0.45 lg/ml biotinylated CaM. Separate samples were probed with a-EGFR, a-P-Tyr or
streptavidin conjugated to peroxidase (Biotin-CaM) as described in the Experimental section.
The arrow points to the approx. 390 kDa complex.
390 kDa that was recognized when probed with a-EGFR and a-
P-Tyr, when the cells were pre-treated with EGF, and with
a-CaM, when CaM was added. However, no CaM signal was
detected in the complex when this regulatory protein was absent
in the assay system. Experiments performed in the absence of
any primary antibody gave no detectable signals (Figure 2,
Control).
We have also performed the experiments using biotinylated
CaM instead of free CaM (Figure 3). Thus the high-molecular-
mass complex of approx. 390 kDa was detected when probed
with a-EGFR and a-P-Tyr, most significantly when the cells
were treated with EGF, and when using steptavidin conjugated
to peroxidase, which detects biotinylated CaM. Similar results
were obtained with the immunoprecipitated receptor from A431
tumour cells (Figure 3A) and EGFR-T17 fibroblasts (Figure 3B).
Figure 4 shows that the relative amount of biotinylated CaM
present in the approx. 390 kDa complex formed upon covalent
cross-linkage of the immunoprecipitated EGFR in the presence
of calcium (Figure 4, Ca#+) diminishes dramatically when the
experiments were performed in the absence of calcium and
presence of a chelating agent (EGTA), or when an excess of free
CaM in the presence of calcium (Figure 4, Ca#+›CaM) was
added before the cross-linking agent BS$. The results were
essentially identical using the immunoprecipitated receptor from
A431 tumour cells (Figure 4, open bars) and EGFR-T17 fibro-
blasts (Figure 4, filled bars).
Direct binding of CaM to the human EGFR
The immunoprecipitated EGFR preparations used to perform
the cross-linkage experiments could have contained some co-
Figure 4 Ca2+-dependent binding of biotinylated CaM to the human EGFR
complex is chased by free CaM
The immunoprecipitated EGFR from 4–7 mg of protein cell extract of A431 tumour cells (open
bars) and from 2.3–2.5 mg of protein cell extract of EGFR-T17 fibroblasts (filled bars) in non-
stimulated cells was subjected to covalent cross-linkage in the presence of 0.45 lg/ml
biotinylated CaM in the presence (Ca2+) and absence (EGTA) of calcium, and in the presence
of calcium plus 45 lg/ml free CaM (Ca2+›CaM) as indicated. The PVDF membrane was
probed with peroxidase-conjugated streptavidin to detect the binding of biotinylated CaM.
Thereafter, the membrane was stripped and re-probed with an a-EGFR, to determine the amount
of receptor present, as described in the Experimental section. The plot shows the mean‡S.E.M.
densitometric intensities of the signals obtained for the biotin-CaM/a-EGFR ratio from three
independent experiments.
immunoprecipitated adaptor proteins or proteins involved in
signalling mediated by this receptor. Therefore it was difficult to
evaluate the real composition of the high-molecular-mass
(approx. 390 kDa) complex formed upon covalent cross-linkage,
besides the fact that the EGFR and CaM (when added) form
part of this complex. Moreover, it is possible that the presence of
Figure 5 Direct binding of biotinylated CaM to the human EGFR and to the
EGFR-associated p190 and p160 CaM-binding proteins
The immunoprecipitated EGFR from 4 mg of protein cell extract of A431 tumour cells (lanes
1) and from 2 mg of protein cell extract of EGFR-T17 fibroblasts (lanes 2) of non-stimulated
cells, was subjected to overlay with 0.45 lg/ml biotinylated CaM in the presence of 0.2 mM
CaCl2 (lanes 1 and 2, left-hand lanes) as described in the Experimental section. Controls in the
presence of EGTA are also presented (lanes 1 and 2, right-hand lanes). The arrows point to
EGFR and the p190 and p160 CaM-binding proteins.
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Figure 6 Binding of biotinylated CaM to the human EGFR was not affected
by EGF or alkaline phosphatase treatment
(A) The immunoprecipitated EGFR from 7 mg of protein cell extract of A431 tumour cells (panel
1) and from 1.8 mg of protein cell extract of EGFR-T17 fibroblasts (panel 2) of non-stimulated
cells or cells stimulated with 10 nM EGF for the indicated periods of time, was subjected to
overlay with 0.45 lg/ml biotinylated CaM in the presence of 0.2 mM CaCl2. The PVDF
membrane was sequentially stripped and re-probed first with an a-P-Tyr and thereafter with an
a-EGFR, as described in the Experimental section. The arrow points to the 170 kDa EGFR. (B)
The immunoprecipitated EGFR from 4 mg of protein cell extract of A431 tumour cells (lanes
1) and from 2.5 mg of protein cell extract of EGFR-T17 fibroblasts (lanes 2) in non-stimulated
cells was incubated in the absence (fi) and presence (›) of 3 units of alkaline phosphatase
(AP) for 30 min at 30 °C in a medium containing 50 mM Tris/HCl (pH 9), 5 mM MgCl2 and
135 mM NaCl. The samples were subjected to overlay with 0.45 lg/ml biotinylated CaM in the
presence of 0.4 mM CaCl2 or 1 mM EGTA as indicated. The PVDF membrane was stripped and
re-probed with an a-EGFR as described in the Experimental section. The arrow points to the
170 kDa EGFR.
unidentified EGFR-associated CaM-binding protein(s) were re-
sponsible for the binding of CaM to this complex. Therefore, it
was necessary to use a different technique to see whether CaM
binds directly to the receptor. For this purpose, we overlaid
the immunoprecipitated EGFR using biotinylated CaM (see
Figure 5). Upon development with streptavidin conjugated to
horseradish peroxidase, which detects biotinylated CaM, we
indeed demonstrated the presence of several positive bands
of 190 kDa (Figure 5, p190), 170 kDa (Figure 5, EGFR) and
160 kDa (Figure 5, p160), in both A431 tumour cells (Figure 5,
lane 1, left) and EGFR-T17 fibroblasts (Figure 5, lane 2, left).
Control experiments performed in the presence of EGTA (Figure
5, lanes 1 and 2, right) are also shown. Moreover, additional
controls performed in the absence of biotinylated CaM only
detected the faint approx. 130 kDa band present in A431 tumour
cells (results not shown).
p190 and p160 appear to be co-immunoprecipitated CaM-
binding proteins associated with the EGFR. However, to ascer-
tain that the prominent 170 kDa CaM-binding protein observed
in these experiments was indeed the EGFR, we performed
similar overlay experiments with biotinylated CaM, and re-
probed the PVDF membrane to look for the presence of the
receptor itself. Figure 6(A) shows that the 170 kDa CaM-binding
protein also gave a positive signal when probed with a-EGFR.
Moreover, the binding of biotinylated CaM to the receptor was
Figure 7 Apparent affinity constant of the human EGFR for CaM
The immunoprecipitated EGFR from 4 mg of protein cell extract of A431 tumour cells (E) and
from 2 mg of protein cell extract of EGFR-T17 fibroblasts (_) in non-stimulated cells was
subjected to overlay with 0.45 lg/ml biotinylated CaM in the presence of 0.2 mM CaCl2 and
the indicated concentrations of free CaM as described in the Experimental section. The
percentage of biotinylated CaM bound to the EGFR is plotted against free CaM concentration.
not affected significantly by the treatment of A431 tumour cells
(Figure 6A, panel 1) or EGFR-T17 fibroblasts (Figure 6A, panel
2) with 10 nM EGF for increasing periods of time. As expected,
however, the incubation of cells with EGF increased the trans-
phosphorylation of the receptor, as detected using a-P-Tyr.
Experiments performed using increasing concentrations of EGF
gave similar results (results not shown).
The EGFR can also be phosphorylated by regulatory
serine}threonine-protein kinases, such as protein kinase C [6–10]
and CaM-dependent protein kinase II [11–13]. Moreover, we
have shown previously that the binding of CaM to a fusion
protein containing the juxtamembrane region (residues 645–660)
of the human EGFR was prevented by the phosphorylation of
Thr’&% by protein kinase C [16]. Therefore, we decided to test
whether the binding of biotinylated CaM to the whole receptor
could be affected by its phosphorylation mediated by these
regulatory serine}threonine-protein kinases.
Experiments performed in the presence of GF109203X and
KN93, cell-permeant inhibitors of protein kinase C and CaM-
dependent protein kinase II, respectively, demonstrated that the
binding of biotinylated CaM to the receptor immunoprecipitated
from both A431 tumour cells and EGFR-T17 fibroblasts was not
affected significantly by the presence of these inhibitors (results
not shown). Moreover, the chronic treatment of A431 tumour
cells with the phorbol ester PMA, used to down-regulate protein
kinase C, did not affect the binding process significantly (results
not shown). Nevertheless, as the basal phosphorylation state of
the immunoprecipitated EGFR catalysed in the cells by regu-
latory serine}threonine-protein kinases was not known, it was of
interest to test whether the treatment of the immunoprecipitated
receptor with alkaline phosphatase modified the binding of
biotinylated CaM. Figure 6(B) shows that this was not the case
in the receptor from A431 tumour cells (Figure 6B, lanes 1) or
EGFR-T17 fibroblasts (Figure 6B, lanes 2). Treatment with
alkaline phosphatase dephosphorylated the EGFR when probed
with a-P-Tyr (results not shown). Moreover, the same Figure also
shows that the binding of biotinylated CaM to the receptor was
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dependent on the presence of Ca#+, as EGTA totally prevented
this process.
Determination of K!d for CaM in the human EGFR
Using the overlay technique with biotinylated CaM described
above, we determined the apparent dissociation constant (K!
d
) of
CaM for the whole human EGFR. Figure 7 shows that the
amount of biotinylated CaM bound to the receptor decreased
progressively in the presence of increasing concentrations of free
CaM. From this plot we determined a K!
d
value for CaM of
0.17 lM in the receptor from A431 tumour cells (Figure 7, E),
and of 0.34 lM in the receptor from EGFR-T17 fibroblasts
(Figure 7, _). We also determined that the K!
d
values for CaM
of the p190 and p160 CaM-binding proteins co-immuno-
precipitated with the EGFR from both cell types were below
0.1 lM (results not shown).
DISCUSSION
The calcium signal generated by the EGFR is of paramount
importance for the regulation of the activity and fate of the
receptor [5]. In this study we demonstrate for the first time that
CaM binds directly to the EGFR. This could explain the
inhibitory action of this modulator on the tyrosine kinase activity
of the receptor [5,14,15].
The covalent complex formed upon incubation of the EGFR
with the cross-linking agent BS$ had an apparent molecular mass
of approx. 390 kDa. However, this complex had no detectable
differences in electrophoretic mobility when the experiments
were performed in the absence or presence of CaM (see Figure 2).
This result is somewhat surprising. However, it is important
to keep in mind that the molecular mass of CaM (16.5 kDa)
is less than 10% of the molecular mass of an EGFR
monomer (170 kDa), and less than 5% of the molecular mass of
the dimeric form of the receptor (340 kDa). Therefore, the
expected change in electrophoretic mobility is near the limits of
the resolution of the SDS}PAGE system used. Nevertheless, the
covalent complex appeared to be significantly larger than the one
expected to be formed by one EGFR dimer bound to one or two
CaM molecules (approx. 356 and 370 kDa, respectively). This
suggests that some additional unidentified proteins may form
part of this complex. However, the IgG used to immuno-
precipitate the receptor does not form part of the approx.
390 kDa complex formed upon treatment with the cross-linkage
agent, as no signal was detected in the immunoblots performed
in the presence of anti-IgG antibodies and in the absence of any
primary antibody (see Figure 2).
The cross-linkage experiments, therefore, did not answer the
question of whether or not CaM binds directly to the EGFR. To
solve this problem, we overlaid the immunoprecipitated EGFR
with biotinylated CaM. The experiments performed with this
technique showed unequivocally that CaM indeed binds directly
to the receptor. Moreover, we detected the presence of additional
CaM-binding proteins in the immunoprecipitated EGFR
preparations. Thus we observed the presence of p190 and p160,
two conspicuous Ca#+-dependent CaM-binding proteins of un-
known nature, which probably interact with the EGFR. We
noticed that the relative proportions of the signal intensities for
biotinylated CaM bound to p190 and p160 CaM-binding proteins
and to the EGFR varied somewhat between preparations. In
general, when the binding of biotinylated CaM to p190 and p160
was very strong the binding of this modulator to the receptor was
weaker. Conversely, a strong binding of biotinylated CaM to the
EGFR was accompanied by weaker binding to the p190 and
p160 CaM-binding proteins. This was independent of the amount
of immunoprecipitated EGFR used in each experiment. More-
over, we occasionally obtained certain preparations where the
binding of biotinylated CaM to the EGFR was very weak or
absent. We also occasionally detected the presence of additional
CaM-binding proteins co-immunoprecipitated with the receptor ;
particularly, an approx. 210 kDa protein phosphorylated at
tyrosine residues, which decreases its phosphorylation upon
activation of the receptor with EGF (results not shown). The
variability in the association of CaM with the different targets
suggests that there could exist very dynamic interactions between
the triad formed by this regulator, the EGFR and the receptor-
associated CaM-binding proteins. The reasons for these changes
are not yet clear. However, it is tempting to speculate that it
could be due to subtle variations in the physiology of the cell,
such as those imposed by the extent of cellular confluence in the
cultures, the actual number of intercellular contacts established
among the cells, and}or the ageing of the cell cultures.
In this study we have shown that the binding of CaM to
the EGFR was not affected by the activation of the receptor by
EGF, the treatment of cells with inhibitors of regulatory protein-
serine}threonine kinases acting on the EGFR or the addition of
alkaline phosphatase to the immunoprecipitated receptor. How-
ever, it is difficult to ascertain whether or not the phosphorylation
state of the receptor could affect the binding of CaM. This is due
to the fact that the proportion of high- and low-affinity receptors
that are activated on the cell surface upon ligand binding in our
experimental conditions is not known. Recently it has been
shown by fluorescence single-molecule imaging that the great
majority of the high-affinity receptors at the surface of living cells
are activated upon addition of EGF [20]. However, the presence
of a large number of low-affinity non-active receptors on the cell
surface could mask the effect of phosphorylation on the binding
of CaM to the receptor. Moreover, the simple determination of
the relative number of high- and low-affinity receptors at the cell
surface may not be any help, as frequently the non-linear
Scatchard plots obtained may hinder analysis of the data [21].
Interestingly, the K!
d
value for CaM determined in this work
for the whole human EGFR (approx. 0.2–0.3 lM) was very close
to the K!
d
determined (0.4 lM) for the cytosolic juxtamembrane
region of the human receptor when forming part of a fusion
protein [16]. Moreover, the apparent inhibition constant of CaM
for the tyrosine kinase activity of the EGFR from rat liver was
demonstrated to be close to 1 lM [14]. These observations
suggest that the cytosolic juxtamembrane segment (residues
645–660) of the EGFR could indeed be responsible for the
binding of CaM in the intact receptor, and that the inhibitory
action exerted by the Ca#+–CaM complex was mediated by its
direct binding to the receptor at this site.
The modulation of the EGFR by CaM may be more complex
than expected, as this calcium modulator not only controls the
activity of CaM-dependent protein kinase II, which phosphoryl-
ates and inhibits the intrinsic tyrosine kinase of the receptor
[11–13], but also performs this inhibition by binding directly to
the receptor ([5,14–16], and this study). Moreover, CaM may
possibly have additional roles to do with the activity and}or fate
of the receptor by interacting with p190 and p160, two EGFR-
associated CaM-binding proteins detected in this work. There-
fore, it is expected that the trio formed by CaM, regulatory
CaM-dependent protein kinases and EGFR-associated CaM-
binding proteins may have physiological significance in the
modulation of the receptor in intact cells.
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